- Home
- RIGL vs GCBC Comparison
RIGL vs GCBC Comparison
Compare RIGL & GCBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- GCBC
- Stock Information
- Founded
- RIGL 1996
- GCBC 1889
- Country
- RIGL United States
- GCBC United States
- Employees
- RIGL N/A
- GCBC N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- GCBC Banks
- Sector
- RIGL Health Care
- GCBC Finance
- Exchange
- RIGL Nasdaq
- GCBC Nasdaq
- Market Cap
- RIGL 486.4M
- GCBC 452.9M
- IPO Year
- RIGL 2000
- GCBC 1998
- Fundamental
- Price
- RIGL $20.09
- GCBC $27.19
- Analyst Decision
- RIGL Buy
- GCBC
- Analyst Count
- RIGL 5
- GCBC 0
- Target Price
- RIGL $34.80
- GCBC N/A
- AVG Volume (30 Days)
- RIGL 223.6K
- GCBC 19.8K
- Earning Date
- RIGL 03-04-2025
- GCBC 01-22-2025
- Dividend Yield
- RIGL N/A
- GCBC 1.33%
- EPS Growth
- RIGL N/A
- GCBC N/A
- EPS
- RIGL 0.22
- GCBC 1.54
- Revenue
- RIGL $157,374,000.00
- GCBC $65,848,000.00
- Revenue This Year
- RIGL $51.34
- GCBC N/A
- Revenue Next Year
- RIGL $15.75
- GCBC N/A
- P/E Ratio
- RIGL $91.32
- GCBC $17.73
- Revenue Growth
- RIGL 21.65
- GCBC N/A
- 52 Week Low
- RIGL $7.48
- GCBC $25.25
- 52 Week High
- RIGL $29.82
- GCBC $37.25
- Technical
- Relative Strength Index (RSI)
- RIGL 45.75
- GCBC 51.00
- Support Level
- RIGL $20.00
- GCBC $27.07
- Resistance Level
- RIGL $21.93
- GCBC $27.62
- Average True Range (ATR)
- RIGL 1.30
- GCBC 0.71
- MACD
- RIGL -0.27
- GCBC 0.16
- Stochastic Oscillator
- RIGL 2.01
- GCBC 77.95
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About GCBC Greene County Bancorp Inc.
Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.